Tazarotene - CAS 118292-40-3
Catalog number: B0084-055312
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Tazarotene could propel either early or late portions of the period leading to differentiation and G0 arrest and is interchangeable with an RARalpha-selective ligand.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-055312 100 mg $198 In stock
B0084-055312 250 mg $398 In stock
Bulk Inquiry
AGN190168, AGN-190168; AGN 190168, Tazarotene, Fabior, Zorac
Canonical SMILES:
1.Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Stein Gold LF Md1. Semin Cutan Med Surg. 2016 Mar;35(2S):S36-S44. doi: 10.12788/j.sder.2016.006.
Psoriasis is a chronic disease that has a substantial effect on quality of life of patients and often needs long-term treatment. Topical treatments for psoriasis include corticosteroids, vitamin D derivatives, tazarotene, anthralin, tacrolimus, pimecrolimus, and newer formulations of tar. Although many of these treatments are effective, they must be prescribed appropriately and used consistently for a period of weeks to months before clinical evidence of improvement can be seen and patients perceive that the treatment is working. As such, medication dosage/schedule, choice of vehicle, and especially patient adherence to medication are key factors for a treatment to be effective. Addressing patient preferences about treatments and concerns about treatment-related toxicities and managing their expectations represent additional aspects of patient care. Therapies such as calcipotriene and betamethasone dipropionate (Cal/BD) fixed combination foam and new drugs and vehicles continuously enhance the treatment landscape for psoriasis.
2.The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition.
Xu Y1, Chen T2, Liao D3, Wu X2, Zhong Y4, Liu S4, Yang H5, Nie Y6. Tumour Biol. 2016 Mar 8. [Epub ahead of print]
Tazarotene-induced gene 3 (TIG3) was first characterized in tazarotene-treated human keratinocytes and identified as a retinoic acid responder gene, an important mediator of antitumor effects by retinoids. In this study, we aim to investigate the inhibitory effect of TIG3 on the growth of liver cancer and explore its underlying mechanism. Human hepatocellular carcinoma (HCC) Hep3B cells were transfected with plasmid GV141 carrying full-length TIG3 complementary DNA (cDNA). The effects of TIG3 on cell proliferation, apoptosis, and migration were determined in vitro. The suppressor effect of TIG3 on tumor growth was evaluated in vivo in a nude mouse HCC model. We observed that TIG3 expression is decreased in the Hep3B cell line as well as primary HCC tumors, and TIG3 expression inversely correlates with Ki-67 expression. Overexpression of TIG3 suppresses tumor growth in HCC both in vitro and in vivo via ERK1/2 inhibition by promoting apoptosis and inhibiting proliferation and migration.
3.Tazarotene foam, 0.1%, for the treatment of acne.
Smith JA1, Narahari S2, Hill D3, Feldman SR4. Expert Opin Drug Saf. 2016 Jan;15(1):99-103. doi: 10.1517/14740338.2016.1117605. Epub 2015 Nov 30.
INTRODUCTION: Acne is a common skin condition of the pilosebaceous units that affects the young and old, ranges from moderate to severe and can be treated with an array of options. Topical retinoids are the initial treatment for acne due to their ability to treat comedones, the starting point of acne.
4.Pharmacologic Treatment Options in Mild, Moderate, and Severe Acne Vulgaris.
Baldwin HE Md1. Semin Cutan Med Surg. 2015 Sep;34(5S):S82-S85. doi: 10.12788/j.sder.2015.0162.
Most patients with acne have a disease that responds to acute treatment and can be controlled long term with a maintenance regimen of topical therapy. It is the minority of patients-generally, but not exclusively-the most severely affected, who respond poorly to acute therapy and require continued systemic therapy. The goals of therapy are resolution of visible lesions, prevention of new lesions, avoidance of scarring, and improvement of patient quality of life. Treatment choices are made on the basis of lesion type, number, and size, with consideration given to the presence of physical and psychological scarring. Semin Cutan Med Surg 34(supp5):S82-S85.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related RAR/RXR Products

AGN 195183
(CAS: 367273-07-2)

RX-195183 is an RARα agonist (Kd=3 nM) with potential antineoplastic activity, modulating the transcription of genes responsible for cell differentiation and pr...

CAS 847239-17-2 UVI 3003

UVI 3003
(CAS: 847239-17-2)

UVI 3003 is a selective and high affinity RXR antagonist. UVI 3003 does not affect the corepressor interaction capacity of the RARα subunit within the context o...

CAS 870773-76-5 AC 261066

AC 261066
(CAS: 870773-76-5)

AC 261066 is a potent RARβ2 agonist (pEC50 = 8.1).

CAS 253310-42-8 BMS 195614

BMS 195614
(CAS: 253310-42-8)

BMS 195614 is a neutral RAR α-selective antagonist (Ki = 2.5 nM) and exhibits no significant effect on nuclear receptor corepressor (NCoR) binding. BMS 195614 m...

CAS 153559-49-0 Bexarotene

(CAS: 153559-49-0)

Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.

CAS 302-79-4 Tretinoin

(CAS: 302-79-4)

Tretinoin, which is a ligand for both the retinoic acid receptor (RAR) and the retinoid X receptor (RXR), can induce granulocytic differentiation and apoptosis ...

CAS 170355-37-0 CD 2314

CD 2314
(CAS: 170355-37-0)

CD 2314 is a potent and selective RARβ receptor agonist (Kd = 145 and >3760 nM for RARβ and RARα receptors, respectively).

CAS 185629-22-5 BMS 961

BMS 961
(CAS: 185629-22-5)

BMS 961 is a potent and selective RARγ agonist (EC50 = 30 and 1000 nM at RARγ and RARβ, respectively) displaying no activity at RARα receptors. It was found tha...

Chemical Structure

CAS 118292-40-3 Tazarotene

Quick Inquiry

Verification code

Featured Items